OTCM
SEPSF
Market cap118kUSD
Nov 19, Last price
0.01USD
Name
Asep Medical Holdings Inc
Chart & performance
P/E
—
P/S
0.49
EPS
—
Div yield, %
—
Shrs. gr., 5y
-7.13%
Rev. gr., 5y
40.63%
Revenues
336k
+1,491.76%
Net income
-5m
L-40.30%
CFO
0
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Asep Medical Holdings Inc. is dedicated to advancing medical solutions, primarily through its subsidiary, ASEP Medical Inc. The company's core focus involves pioneering an early diagnostic method for Sepsis, as well as developing innovative peptide-based therapeutic treatments applicable to a variety of medical conditions. Established in 2020, this Vancouver, Canada-based firm was formerly known as Trenchant Life Sciences Investment Corp. before adopting its present identity.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||